{"protocolSection": {"identificationModule": {"nctId": "NCT01810380", "orgStudyIdInfo": {"id": "14644A"}, "secondaryIdInfos": [{"id": "2012-002252-17", "type": "EUDRACT_NUMBER"}], "organization": {"fullName": "H. Lundbeck A/S", "class": "INDUSTRY"}, "briefTitle": "Brexpiprazole in Patients With Acute Schizophrenia", "officialTitle": "Interventional, Randomised, Double-blind, Parallel-group, Placebo-controlled, Active-reference, Flexible-dose Study of Brexpiprazole in Patients With Acute Schizophrenia"}, "statusModule": {"statusVerifiedDate": "2017-02", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2013-03"}, "primaryCompletionDateStruct": {"date": "2014-12", "type": "ACTUAL"}, "completionDateStruct": {"date": "2014-12", "type": "ACTUAL"}, "studyFirstSubmitDate": "2013-03-11", "studyFirstSubmitQcDate": "2013-03-11", "studyFirstPostDateStruct": {"date": "2013-03-13", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2015-12-30", "resultsFirstSubmitQcDate": "2016-02-26", "resultsFirstPostDateStruct": {"date": "2016-03-29", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2017-02-08", "lastUpdatePostDateStruct": {"date": "2017-03-16", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "H. Lundbeck A/S", "class": "INDUSTRY"}, "collaborators": [{"name": "Otsuka Pharmaceutical Co., Ltd.", "class": "INDUSTRY"}]}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "To determine the efficacy and safety of brexpiprazole for the treatment of adults experiencing an acute episode of schizophrenia."}, "conditionsModule": {"conditions": ["Schizophrenia"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 468, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Placebo", "type": "PLACEBO_COMPARATOR", "interventionNames": ["Drug: Placebo"]}, {"label": "Brexpiprazole", "type": "EXPERIMENTAL", "description": "Patients randomised to brexpiprazole received 1mg/day on Day 1, 2mg/day on Day 2, 3mg/day on Day 3 (uptitration); the dose could be adjusted from Day 4 onwards to 2, 3, or 4mg/day to optimise the clinical effect and tolerability.", "interventionNames": ["Drug: Brexpiprazole"]}, {"label": "Quetiapine extended release", "type": "OTHER", "description": "Active Reference. Patients randomised to quetiapine received 300mg/day on Day 1, 600mg/day on Days 2 and 3 (uptitration); the dose could be adjusted from Day 4 onwards to 400, 600, or 800mg/day to optimise the clinical effect and tolerability.", "interventionNames": ["Drug: Quetiapine extended release"]}], "interventions": [{"type": "DRUG", "name": "Placebo", "description": "Once daily as tablets and capsules, orally", "armGroupLabels": ["Placebo"]}, {"type": "DRUG", "name": "Brexpiprazole", "description": "2-4 mg/day, once daily, tablets, orally", "armGroupLabels": ["Brexpiprazole"]}, {"type": "DRUG", "name": "Quetiapine extended release", "description": "400-800 mg/day, once daily, encapsulated tablets, orally", "armGroupLabels": ["Quetiapine extended release"], "otherNames": ["Seroquel XL\u00ae/XR\u00ae"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change From Baseline to Week 6 in PANSS Total Score", "description": "The Positive and Negative Syndrome Scale (PANSS) is a 30-item scale for assessing the symptoms of schizophrenia. For each PANSS item, symptom severity was rated on a 7-point scale, from 1=absent to 7=extreme. The PANSS total score (30 items) ranged from 30 to 210 with a higher score indicating greater severity of symptoms.", "timeFrame": "Baseline and Week 6"}], "secondaryOutcomes": [{"measure": "Change From Baseline to Week 6 in CGI-S Score", "description": "The Clinical Global Impression - Severity of Illness (CGI-S) provides the clinician's impression of the patient's current state of mental illness.\n\nThe clinician uses his or her clinical experience of this patient population to rate the severity of the patient's current mental illness on a 7-point scale ranging from 1 (normal - not at all ill) to 7 (among the most extremely ill patients).", "timeFrame": "Baseline and Week 6"}, {"measure": "CGI-I Score at Week 6", "description": "The Clinical Global Impression - Global Improvement (CGI-I) provides the clinician's impression of the patient's improvement (or worsening).\n\nThe clinician assesses the patient's condition relative to a baseline on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). In all cases, the assessment should be made independent of whether the rater believes the improvement is drug-related or not.", "timeFrame": "Week 6"}, {"measure": "Change From Baseline to Week 6 in PANSS Positive Subscale Score", "description": "The Positive and Negative Syndrome Scale (PANSS) is a clinician rated scale designed to measure severity of psychopathology in adult patients with schizophrenia, schizoaffective disorders and other psychotic disorders. It emphasizes positive and negative symptoms. The PANSS Positive Subscale score is calculated from 7 items (for example: delusions, conceptual disorganization and hallucinatory behaviour). Symptom severity was rated on a 7-point scale, from 1=absent to 7=extreme. Higher score indicating greater severity of symptoms", "timeFrame": "Baseline and Week 6"}, {"measure": "Change From Baseline to Week 6 in PANSS Negative Subscale Score", "description": "The Positive and Negative Syndrome Scale (PANSS) is a clinician rated scale designed to measure severity of psychopathology in adult patients with schizophrenia, schizoaffective disorders and other psychotic disorders. It emphasizes positive and negative symptoms. The PANSS Negative Subscale score is calculated from 7 items (for example: blunted affect, emotional withdrawal and poor rapport). Symptom severity was rated on a 7-point scale, from 1=absent to 7=extreme. Higher score indicating greater severity of symptoms", "timeFrame": "Baseline and Week 6"}, {"measure": "Change From Baseline to Week 6 in PANSS General Psychopathology Subscale Score", "description": "The Positive and Negative Syndrome Scale (PANSS) is a clinician rated scale designed to measure severity of psychopathology in adult patients with schizophrenia, schizoaffective disorders and other psychotic disorders. It emphasizes positive and negative symptoms. The PANSS General Psychopathology Subscale score is calculated from 16 items (for example: somatic concern, anxiety and guilt feelings). Symptom severity was rated on a 7-point scale, from 1=absent to 7=extreme. Higher score indicating greater severity of symptoms", "timeFrame": "Baseline and Week 6"}, {"measure": "Change From Baseline to Week 6 in PANSS Excited Component Score", "description": "The Positive and Negative Syndrome Scale (PANSS) is a clinician rated scale designed to measure severity of psychopathology in adult patients with schizophrenia, schizoaffective disorders and other psychotic disorders. It emphasizes positive and negative symptoms. The PANSS Excited Component score is calculated from 5 items (for example: poor impulse control, tension and hostility). Symptom severity was rated on a 7-point scale, from 1=absent to 7=extreme. Higher score indicating greater severity of symptoms", "timeFrame": "Baseline and Week 6"}, {"measure": "Change From Baseline to Week 6 in PANSS Marder Factor Scores: Negative Symptoms", "description": "The Positive and Negative Syndrome Scale (PANSS) is a clinician rated scale designed to measure severity of psychopathology in adult patients with schizophrenia, schizoaffective disorders and other psychotic disorders. It emphasizes positive and negative symptoms. The PANSS Marder Factor scores: negative symptoms is calculated from 7 items (for example: blunted affect, emotional withdrawal and motor retardation). Symptom severity was rated on a 7-point scale, from 1=absent to 7=extreme. Higher score indicating greater severity of symptoms", "timeFrame": "Baseline and Week 6"}, {"measure": "Change From Baseline to Week 6 in PANSS Marder Factor Scores: Positive Symptoms", "description": "The Positive and Negative Syndrome Scale (PANSS) is a clinician rated scale designed to measure severity of psychopathology in adult patients with schizophrenia, schizoaffective disorders and other psychotic disorders. It emphasizes positive and negative symptoms. The PANSS Marder Factor scores: positive symptoms is calculated from 8 items (for example: delusions, conceptual disorganization and stereotype thinking). Symptom severity was rated on a 7-point scale, from 1=absent to 7=extreme. Higher score indicating greater severity of symptoms", "timeFrame": "Baseline and Week 6"}, {"measure": "Change From Baseline to Week 6 in PANSS Marder Factor Scores: Disorganized Thoughts", "description": "The Positive and Negative Syndrome Scale (PANSS) is a clinician rated scale designed to measure severity of psychopathology in adult patients with schizophrenia, schizoaffective disorders and other psychotic disorders. It emphasizes positive and negative symptoms. The PANSS Marder Factor scores: disorganized thoughts is calculated from 7 items (for example: conceptual disorganization, difficulty in abstract thinking and mannerisms and posturing). Symptom severity was rated on a 7-point scale, from 1=absent to 7=extreme. Higher score indicating greater severity of symptoms", "timeFrame": "Baseline and Week 6"}, {"measure": "Change From Baseline to Week 6 in PANSS Marder Factor Scores: Uncontrolled Hostility/Excitement", "description": "The Positive and Negative Syndrome Scale (PANSS) is a clinician rated scale designed to measure severity of psychopathology in adult patients with schizophrenia, schizoaffective disorders and other psychotic disorders. It emphasizes positive and negative symptoms. The PANSS Marder Factor scores: uncontrolled hostility/excitement is calculated from 4 items (for example: excitement, hostility, and uncooperativeness).Symptom severity was rated on a 7-point scale, from 1=absent to 7=extreme. Higher score indicating greater severity of symptoms", "timeFrame": "Baseline and Week 6"}, {"measure": "Change From Baseline to Week 6 in PANSS Marder Factor Scores: Anxiety/Depression", "description": "The Positive and Negative Syndrome Scale (PANSS) is a clinician rated scale designed to measure severity of psychopathology in adult patients with schizophrenia, schizoaffective disorders and other psychotic disorders. It emphasizes positive and negative symptoms. The PANSS Marder Factor scores: anxiety/depression is calculated from 4 items (for example: anxiety, guilt feelings, and tension). Symptom severity was rated on a 7-point scale, from 1=absent to 7=extreme. Higher score indicating greater severity of symptoms", "timeFrame": "Baseline and Week 6"}, {"measure": "Discontinuation Due to Lack of Efficacy During the Study", "description": "Discontinuation due to lack of efficacy was based on the primary reason for withdrawal", "timeFrame": "Baseline to Week 6"}, {"measure": "Response Rate at Week 6", "description": "The response rate was defined as a reduction of \u226530% from baseline in PANSS total score OR a CGI-I score of 1 or 2", "timeFrame": "Baseline and Week 6"}, {"measure": "Change From Baseline to Week 6 in PSP Total Score", "description": "The Personal and Social Performance Scale (PSP) is a clinician-rated scale designed and validated to measure a patient's current level of social functioning. The PSP scale consists of a 100-point single-item rating scale, subdivided into 10 equal intervals. Scores of 1 to 10 indicate lack of autonomy in basic functioning, whereas scores of 91 to 100 reflect excellent functioning. The total score is rated by the investigator and is based on an algorithm which takes both the ratings of the 4 primary domains of PSP, and the combination of these ratings into account. The 4 primary domains are: socially useful activities (including work and study), personal and social relationships, self-care, and disturbing and aggressive behaviours. The 4 domains are assessed on a 6-point scale, from absent to very severe. A higher score indicates a better performance.", "timeFrame": "Baseline and Week 6"}, {"measure": "PSP Functional Remission Rate at Week 6", "description": "The PSP functional remission rate was defined as a PSP total score \u226571", "timeFrame": "Week 6"}, {"measure": "PSP Functional Response Rate at Week 6", "description": "The PSP functional response rate was defined as \u226510 point improvement from Baseline on the PSP total score", "timeFrame": "Week 6"}, {"measure": "PSP Domain D: Disturbing and Aggressive Behaviours at Week 6", "description": "PSP domain D: disturbing and aggressive behaviours were categorised as \"aggressive\" (corresponding to mild, manifest, marked, severe, or very severe) or \"nonaggressive\" (corresponding to absent)", "timeFrame": "Week 6"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* The patient has schizophrenia, diagnosed according to DSM-IV-TR\u2122 and confirmed by the Mini International Neuropsychiatric Interview (MINI).\n* The patient has an acute exacerbation of psychotic symptoms and marked deterioration of usual function.\n* The patient is willing to be hospitalised from the Screening Visit through Week 6.\n* The patient will benefit from hospitalisation or continued hospitalisation for treatment of a current acute relapse of schizophrenia at study entry.\n* The patient has a history of relapse and/or exacerbation of symptoms when not receiving antipsychotic treatment, excluding the current episode.\n* The patient agrees to protocol-defined use of effective contraception.\n\nExclusion Criteria:\n\n* The patient has a current Axis I diagnosis (DSM-IV-TR\u2122 criteria) other than schizophrenia established as primary diagnosis.\n* The patient suffers from a current Axis II diagnosis (DSM-IV-TR\u2122 criteria).\n* The patient suffers from mental retardation, organic mental disorders, or mental disorders due to a general medical condition (DSM-IV-TR\u2122 criteria).\n* The patient, in the opinion of the investigator or according to Columbia Suicide Severity Rating Scale (C-SSRS), is at significant risk of suicide.\n* The patient has clinically significant tardive dyskinesia or severe akathisia at enrolment.\n* The patient has a history of neuroleptic malignant syndrome.\n* The patient has any relevant medical history or current presence of systemic disease.\n* The patient has, at the Screening Visit an abnormal ECG or other abnormal ECG tests that are, in the investigator's opinion, clinically significant.\n* The patient has a history of cancer, other than basal cell or Stage 1 squamous cell carcinoma of the skin, that has not been in remission for \\>5 years prior to the first dose of brexpiprazole.\n* The patient is, in the investigator's opinion, unlikely to comply with the protocol or is unsuitable for any reason.\n\nOther inclusion and exclusion criteria may apply.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "65 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Email contact via H. Lundbeck A/S", "affiliation": "LundbeckClinicalTrials@lundbeck.com", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "US009", "city": "Escondido", "state": "California", "zip": "92025", "country": "United States", "geoPoint": {"lat": 33.11921, "lon": -117.08642}}]}, "referencesModule": {"references": [{"pmid": "35235720", "type": "DERIVED", "citation": "Correll CU, He Y, Therrien F, MacKenzie E, Meehan SR, Weiss C, Hefting N, Hobart M. Effects of Brexpiprazole on Functioning in Patients With Schizophrenia: Post Hoc Analysis of Short- and Long-Term Studies. J Clin Psychiatry. 2022 Mar 1;83(2):20m13793. doi: 10.4088/JCP.20m13793."}, {"pmid": "34901863", "type": "DERIVED", "citation": "Marder SR, Meehan SR, Weiss C, Chen D, Hobart M, Hefting N. Effects of Brexpiprazole Across Symptom Domains in Patients With Schizophrenia: Post Hoc Analysis of Short- and Long-Term Studies. Schizophr Bull Open. 2021 May 1;2(1):sgab014. doi: 10.1093/schizbullopen/sgab014. eCollection 2021 Jan."}], "seeAlsoLinks": [{"label": "EMA EudraCT Results: 2012-002252-17", "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-002252-17/results"}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Placebo", "description": "Placebo: Once daily as tablets and capsules, orally"}, {"id": "FG001", "title": "Brexpiprazole", "description": "Brexpiprazole: 2-4 mg/day, once daily, tablets, orally"}, {"id": "FG002", "title": "Quetiapine Extended Release", "description": "Active Reference\n\nQuetiapine extended release: 400-800 mg/day, once daily, encapsulated tablets, orally"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "163"}, {"groupId": "FG001", "numSubjects": "151"}, {"groupId": "FG002", "numSubjects": "154"}]}, {"type": "Treated", "achievements": [{"groupId": "FG000", "numSubjects": "161"}, {"groupId": "FG001", "numSubjects": "150"}, {"groupId": "FG002", "numSubjects": "153"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "108"}, {"groupId": "FG001", "numSubjects": "113"}, {"groupId": "FG002", "numSubjects": "122"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "55"}, {"groupId": "FG001", "numSubjects": "38"}, {"groupId": "FG002", "numSubjects": "32"}]}], "dropWithdraws": [{"type": "Randomised not treated", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "1"}]}, {"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "11"}, {"groupId": "FG001", "numSubjects": "14"}, {"groupId": "FG002", "numSubjects": "4"}]}, {"type": "Lack of Efficacy", "reasons": [{"groupId": "FG000", "numSubjects": "24"}, {"groupId": "FG001", "numSubjects": "10"}, {"groupId": "FG002", "numSubjects": "11"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "6"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "6"}]}, {"type": "Administrative or other reasons", "reasons": [{"groupId": "FG000", "numSubjects": "11"}, {"groupId": "FG001", "numSubjects": "13"}, {"groupId": "FG002", "numSubjects": "9"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "all-patients-treated set (APTS)", "groups": [{"id": "BG000", "title": "Placebo", "description": "Placebo: Once daily as tablets and capsules, orally"}, {"id": "BG001", "title": "Brexpiprazole", "description": "Brexpiprazole: 2-4 mg/day, once daily, tablets, orally"}, {"id": "BG002", "title": "Quetiapine Extended Release", "description": "Active Reference\n\nQuetiapine extended release: 400-800 mg/day, once daily, encapsulated tablets, orally"}, {"id": "BG003", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "161"}, {"groupId": "BG001", "value": "150"}, {"groupId": "BG002", "value": "153"}, {"groupId": "BG003", "value": "464"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "40.85", "spread": "10.56"}, {"groupId": "BG001", "value": "39.68", "spread": "10.87"}, {"groupId": "BG002", "value": "41.12", "spread": "10.91"}, {"groupId": "BG003", "value": "40.56", "spread": "10.77"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "70"}, {"groupId": "BG001", "value": "66"}, {"groupId": "BG002", "value": "64"}, {"groupId": "BG003", "value": "200"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "91"}, {"groupId": "BG001", "value": "84"}, {"groupId": "BG002", "value": "89"}, {"groupId": "BG003", "value": "264"}]}]}]}, {"title": "Race (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "American Indian or Alaska Native", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "1"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "3"}]}, {"title": "Native Hawaiian or Other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "1"}, {"groupId": "BG003", "value": "2"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "35"}, {"groupId": "BG001", "value": "33"}, {"groupId": "BG002", "value": "38"}, {"groupId": "BG003", "value": "106"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "123"}, {"groupId": "BG001", "value": "113"}, {"groupId": "BG002", "value": "113"}, {"groupId": "BG003", "value": "349"}]}, {"title": "More than one race", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "1"}, {"groupId": "BG003", "value": "3"}]}]}]}, {"title": "Region of Enrollment", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "United States", "categories": [{"measurements": [{"groupId": "BG000", "value": "50"}, {"groupId": "BG001", "value": "52"}, {"groupId": "BG002", "value": "56"}, {"groupId": "BG003", "value": "158"}]}]}, {"title": "Estonia", "categories": [{"measurements": [{"groupId": "BG000", "value": "4"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "4"}, {"groupId": "BG003", "value": "11"}]}]}, {"title": "France", "categories": [{"measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "1"}, {"groupId": "BG003", "value": "2"}]}]}, {"title": "Poland", "categories": [{"measurements": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "5"}, {"groupId": "BG002", "value": "5"}, {"groupId": "BG003", "value": "15"}]}]}, {"title": "Romania", "categories": [{"measurements": [{"groupId": "BG000", "value": "14"}, {"groupId": "BG001", "value": "13"}, {"groupId": "BG002", "value": "11"}, {"groupId": "BG003", "value": "38"}]}]}, {"title": "Serbia", "categories": [{"measurements": [{"groupId": "BG000", "value": "13"}, {"groupId": "BG001", "value": "11"}, {"groupId": "BG002", "value": "11"}, {"groupId": "BG003", "value": "35"}]}]}, {"title": "Slovakia", "categories": [{"measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "1"}, {"groupId": "BG003", "value": "3"}]}]}, {"title": "Ukraine", "categories": [{"measurements": [{"groupId": "BG000", "value": "30"}, {"groupId": "BG001", "value": "28"}, {"groupId": "BG002", "value": "29"}, {"groupId": "BG003", "value": "87"}]}]}, {"title": "Russian Federation", "categories": [{"measurements": [{"groupId": "BG000", "value": "43"}, {"groupId": "BG001", "value": "37"}, {"groupId": "BG002", "value": "35"}, {"groupId": "BG003", "value": "115"}]}]}]}, {"title": "Time since schizophrenia diagnosis (years)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "14.15", "spread": "9.35"}, {"groupId": "BG001", "value": "12.88", "spread": "9.43"}, {"groupId": "BG002", "value": "13.78", "spread": "9.49"}, {"groupId": "BG003", "value": "13.62", "spread": "9.42"}]}]}]}, {"title": "Time since first antipsychotic treatment (years)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "14.48", "spread": "8.98"}, {"groupId": "BG001", "value": "13.43", "spread": "9.19"}, {"groupId": "BG002", "value": "14.31", "spread": "9.34"}, {"groupId": "BG003", "value": "14.08", "spread": "9.16"}]}]}]}, {"title": "PANSS total score", "description": "The Positive and Negative Syndrome Scale (PANSS) is a 30-item scale for assessing the symptoms of schizophrenia. For each PANSS item, symptom severity was rated on a 7-point scale, from 1=absent to 7=extreme. The PANSS total score (30 items) ranged from 30 to 210 with a higher score indicating greater severity of symptoms. PANSS total score is reported for the full analysis set (FAS); PBO=159, Brex=150, Que=150, and no total value was summarised for reporting", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "units on a scale", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "98.38", "spread": "10.30"}, {"groupId": "BG001", "value": "97.82", "spread": "10.25"}, {"groupId": "BG002", "value": "98.82", "spread": "10.83"}, {"groupId": "BG003", "value": "98.34", "spread": "10.45"}]}]}]}, {"title": "CGI-S Score", "description": "The Clinical Global Impression - Severity of Illness (CGI-S) provides the clinician's impression of the patient's current state of mental illness. The clinician uses his or her clinical experience of this patient population to rate the severity of the patient's current mental illness on a 7-point scale ranging from 1 (normal - not at all ill) to 7 (among the most extremely ill patients). CGI-S score is reported for the full analysis set (FAS); PBO=159, Brex=150, Que=150, and no total value was summarised for reporting", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "units on a scale", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "4.94", "spread": "0.57"}, {"groupId": "BG001", "value": "4.96", "spread": "0.59"}, {"groupId": "BG002", "value": "4.98", "spread": "0.57"}, {"groupId": "BG003", "value": "4.96", "spread": "0.58"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change From Baseline to Week 6 in PANSS Total Score", "description": "The Positive and Negative Syndrome Scale (PANSS) is a 30-item scale for assessing the symptoms of schizophrenia. For each PANSS item, symptom severity was rated on a 7-point scale, from 1=absent to 7=extreme. The PANSS total score (30 items) ranged from 30 to 210 with a higher score indicating greater severity of symptoms.", "populationDescription": "Full-analysis set (FAS)", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "units on a scale", "timeFrame": "Baseline and Week 6", "groups": [{"id": "OG000", "title": "Placebo", "description": "Placebo: Once daily as tablets and capsules, orally"}, {"id": "OG001", "title": "Brexpiprazole", "description": "Brexpiprazole: 2-4 mg/day, once daily, tablets, orally"}, {"id": "OG002", "title": "Quetiapine Extended Release", "description": "Active Reference\n\nQuetiapine extended release: 400-800 mg/day, once daily, encapsulated tablets, orally"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "159"}, {"groupId": "OG001", "value": "150"}, {"groupId": "OG002", "value": "150"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-15.9", "spread": "1.5"}, {"groupId": "OG001", "value": "-20.0", "spread": "1.5"}, {"groupId": "OG002", "value": "-24.0", "spread": "1.5"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "The overall significance level was 0.05. The primary and the key secondary endpoints were tested hierarchically. Only if the primary endpoint was statistically significant would confirmatory testing continue with the key secondary endpoint.", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0560", "pValueComment": "For all efficacy analyses the primary comparison is the difference between brexpiprazole 2 to 4 mg/day and placebo at Week 6.", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Pooled site, visit, treatment as fixed effects, baseline score as continuous covariate, treatment-by-visit and baseline score-by-visit as interactions", "paramType": "Least square mean difference", "paramValue": "-4.1", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-8.2", "ciUpperLimit": "0.1", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "2.1"}, {"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0002", "statisticalMethod": "Mixed Models Analysis", "paramType": "Least square mean difference", "paramValue": "-8.0", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-12.2", "ciUpperLimit": "-3.9", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "2.1"}]}, {"type": "SECONDARY", "title": "Change From Baseline to Week 6 in CGI-S Score", "description": "The Clinical Global Impression - Severity of Illness (CGI-S) provides the clinician's impression of the patient's current state of mental illness.\n\nThe clinician uses his or her clinical experience of this patient population to rate the severity of the patient's current mental illness on a 7-point scale ranging from 1 (normal - not at all ill) to 7 (among the most extremely ill patients).", "populationDescription": "FAS", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "units on a scale", "timeFrame": "Baseline and Week 6", "groups": [{"id": "OG000", "title": "Placebo", "description": "Placebo: Once daily as tablets and capsules, orally"}, {"id": "OG001", "title": "Brexpiprazole", "description": "Brexpiprazole: 2-4 mg/day, once daily, tablets, orally"}, {"id": "OG002", "title": "Quetiapine Extended Release", "description": "Active Reference\n\nQuetiapine extended release: 400-800 mg/day, once daily, encapsulated tablets, orally"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "159"}, {"groupId": "OG001", "value": "150"}, {"groupId": "OG002", "value": "150"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.9", "spread": "0.1"}, {"groupId": "OG001", "value": "-1.2", "spread": "0.1"}, {"groupId": "OG002", "value": "-1.4", "spread": "0.1"}]}]}]}, {"type": "SECONDARY", "title": "CGI-I Score at Week 6", "description": "The Clinical Global Impression - Global Improvement (CGI-I) provides the clinician's impression of the patient's improvement (or worsening).\n\nThe clinician assesses the patient's condition relative to a baseline on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). In all cases, the assessment should be made independent of whether the rater believes the improvement is drug-related or not.", "populationDescription": "FAS", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "units on a scale", "timeFrame": "Week 6", "groups": [{"id": "OG000", "title": "Placebo", "description": "Placebo: Once daily as tablets and capsules, orally"}, {"id": "OG001", "title": "Brexpiprazole", "description": "Brexpiprazole: 2-4 mg/day, once daily, tablets, orally"}, {"id": "OG002", "title": "Quetiapine Extended Release", "description": "Active Reference\n\nQuetiapine extended release: 400-800 mg/day, once daily, encapsulated tablets, orally"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "159"}, {"groupId": "OG001", "value": "150"}, {"groupId": "OG002", "value": "150"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "3.0", "spread": "0.1"}, {"groupId": "OG001", "value": "2.7", "spread": "0.1"}, {"groupId": "OG002", "value": "2.5", "spread": "0.1"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline to Week 6 in PANSS Positive Subscale Score", "description": "The Positive and Negative Syndrome Scale (PANSS) is a clinician rated scale designed to measure severity of psychopathology in adult patients with schizophrenia, schizoaffective disorders and other psychotic disorders. It emphasizes positive and negative symptoms. The PANSS Positive Subscale score is calculated from 7 items (for example: delusions, conceptual disorganization and hallucinatory behaviour). Symptom severity was rated on a 7-point scale, from 1=absent to 7=extreme. Higher score indicating greater severity of symptoms", "populationDescription": "FAS", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "units on a scale", "timeFrame": "Baseline and Week 6", "groups": [{"id": "OG000", "title": "Placebo", "description": "Placebo: Once daily as tablets and capsules, orally"}, {"id": "OG001", "title": "Brexpiprazole", "description": "Brexpiprazole: 2-4 mg/day, once daily, tablets, orally"}, {"id": "OG002", "title": "Quetiapine Extended Release", "description": "Active Reference\n\nQuetiapine extended release: 400-800 mg/day, once daily, encapsulated tablets, orally"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "159"}, {"groupId": "OG001", "value": "150"}, {"groupId": "OG002", "value": "150"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-5.4", "spread": "0.5"}, {"groupId": "OG001", "value": "-7.0", "spread": "0.5"}, {"groupId": "OG002", "value": "-8.1", "spread": "0.5"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline to Week 6 in PANSS Negative Subscale Score", "description": "The Positive and Negative Syndrome Scale (PANSS) is a clinician rated scale designed to measure severity of psychopathology in adult patients with schizophrenia, schizoaffective disorders and other psychotic disorders. It emphasizes positive and negative symptoms. The PANSS Negative Subscale score is calculated from 7 items (for example: blunted affect, emotional withdrawal and poor rapport). Symptom severity was rated on a 7-point scale, from 1=absent to 7=extreme. Higher score indicating greater severity of symptoms", "populationDescription": "FAS", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "units on a scale", "timeFrame": "Baseline and Week 6", "groups": [{"id": "OG000", "title": "Placebo", "description": "Placebo: Once daily as tablets and capsules, orally"}, {"id": "OG001", "title": "Brexpiprazole", "description": "Brexpiprazole: 2-4 mg/day, once daily, tablets, orally"}, {"id": "OG002", "title": "Quetiapine Extended Release", "description": "Active Reference\n\nQuetiapine extended release: 400-800 mg/day, once daily, encapsulated tablets, orally"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "159"}, {"groupId": "OG001", "value": "150"}, {"groupId": "OG002", "value": "150"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-3.1", "spread": "0.4"}, {"groupId": "OG001", "value": "-3.7", "spread": "0.4"}, {"groupId": "OG002", "value": "-4.5", "spread": "0.4"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline to Week 6 in PANSS General Psychopathology Subscale Score", "description": "The Positive and Negative Syndrome Scale (PANSS) is a clinician rated scale designed to measure severity of psychopathology in adult patients with schizophrenia, schizoaffective disorders and other psychotic disorders. It emphasizes positive and negative symptoms. The PANSS General Psychopathology Subscale score is calculated from 16 items (for example: somatic concern, anxiety and guilt feelings). Symptom severity was rated on a 7-point scale, from 1=absent to 7=extreme. Higher score indicating greater severity of symptoms", "populationDescription": "FAS", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "units on a scale", "timeFrame": "Baseline and Week 6", "groups": [{"id": "OG000", "title": "Placebo", "description": "Placebo: Once daily as tablets and capsules, orally"}, {"id": "OG001", "title": "Brexpiprazole", "description": "Brexpiprazole: 2-4 mg/day, once daily, tablets, orally"}, {"id": "OG002", "title": "Quetiapine Extended Release", "description": "Active Reference\n\nQuetiapine extended release: 400-800 mg/day, once daily, encapsulated tablets, orally"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "159"}, {"groupId": "OG001", "value": "150"}, {"groupId": "OG002", "value": "150"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-8.2", "spread": "0.7"}, {"groupId": "OG001", "value": "-9.9", "spread": "0.7"}, {"groupId": "OG002", "value": "-11.6", "spread": "0.7"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline to Week 6 in PANSS Excited Component Score", "description": "The Positive and Negative Syndrome Scale (PANSS) is a clinician rated scale designed to measure severity of psychopathology in adult patients with schizophrenia, schizoaffective disorders and other psychotic disorders. It emphasizes positive and negative symptoms. The PANSS Excited Component score is calculated from 5 items (for example: poor impulse control, tension and hostility). Symptom severity was rated on a 7-point scale, from 1=absent to 7=extreme. Higher score indicating greater severity of symptoms", "populationDescription": "FAS", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "units on a scale", "timeFrame": "Baseline and Week 6", "groups": [{"id": "OG000", "title": "Placebo", "description": "Placebo: Once daily as tablets and capsules, orally"}, {"id": "OG001", "title": "Brexpiprazole", "description": "Brexpiprazole: 2-4 mg/day, once daily, tablets, orally"}, {"id": "OG002", "title": "Quetiapine Extended Release", "description": "Active Reference\n\nQuetiapine extended release: 400-800 mg/day, once daily, encapsulated tablets, orally"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "159"}, {"groupId": "OG001", "value": "150"}, {"groupId": "OG002", "value": "150"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-2.5", "spread": "0.3"}, {"groupId": "OG001", "value": "-3.3", "spread": "0.3"}, {"groupId": "OG002", "value": "-3.9", "spread": "0.3"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline to Week 6 in PANSS Marder Factor Scores: Negative Symptoms", "description": "The Positive and Negative Syndrome Scale (PANSS) is a clinician rated scale designed to measure severity of psychopathology in adult patients with schizophrenia, schizoaffective disorders and other psychotic disorders. It emphasizes positive and negative symptoms. The PANSS Marder Factor scores: negative symptoms is calculated from 7 items (for example: blunted affect, emotional withdrawal and motor retardation). Symptom severity was rated on a 7-point scale, from 1=absent to 7=extreme. Higher score indicating greater severity of symptoms", "populationDescription": "FAS", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "units on a scale", "timeFrame": "Baseline and Week 6", "groups": [{"id": "OG000", "title": "Placebo", "description": "Placebo: Once daily as tablets and capsules, orally"}, {"id": "OG001", "title": "Brexpiprazole", "description": "Brexpiprazole: 2-4 mg/day, once daily, tablets, orally"}, {"id": "OG002", "title": "Quetiapine Extended Release", "description": "Active Reference\n\nQuetiapine extended release: 400-800 mg/day, once daily, encapsulated tablets, orally"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "159"}, {"groupId": "OG001", "value": "150"}, {"groupId": "OG002", "value": "150"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-3.6", "spread": "0.4"}, {"groupId": "OG001", "value": "-4.3", "spread": "0.4"}, {"groupId": "OG002", "value": "-4.8", "spread": "0.4"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline to Week 6 in PANSS Marder Factor Scores: Positive Symptoms", "description": "The Positive and Negative Syndrome Scale (PANSS) is a clinician rated scale designed to measure severity of psychopathology in adult patients with schizophrenia, schizoaffective disorders and other psychotic disorders. It emphasizes positive and negative symptoms. The PANSS Marder Factor scores: positive symptoms is calculated from 8 items (for example: delusions, conceptual disorganization and stereotype thinking). Symptom severity was rated on a 7-point scale, from 1=absent to 7=extreme. Higher score indicating greater severity of symptoms", "populationDescription": "FAS", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "units on a scale", "timeFrame": "Baseline and Week 6", "groups": [{"id": "OG000", "title": "Placebo", "description": "Placebo: Once daily as tablets and capsules, orally"}, {"id": "OG001", "title": "Brexpiprazole", "description": "Brexpiprazole: 2-4 mg/day, once daily, tablets, orally"}, {"id": "OG002", "title": "Quetiapine Extended Release", "description": "Active Reference\n\nQuetiapine extended release: 400-800 mg/day, once daily, encapsulated tablets, orally"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "159"}, {"groupId": "OG001", "value": "150"}, {"groupId": "OG002", "value": "150"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-5.7", "spread": "0.5"}, {"groupId": "OG001", "value": "-7.1", "spread": "0.5"}, {"groupId": "OG002", "value": "-8.4", "spread": "0.5"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline to Week 6 in PANSS Marder Factor Scores: Disorganized Thoughts", "description": "The Positive and Negative Syndrome Scale (PANSS) is a clinician rated scale designed to measure severity of psychopathology in adult patients with schizophrenia, schizoaffective disorders and other psychotic disorders. It emphasizes positive and negative symptoms. The PANSS Marder Factor scores: disorganized thoughts is calculated from 7 items (for example: conceptual disorganization, difficulty in abstract thinking and mannerisms and posturing). Symptom severity was rated on a 7-point scale, from 1=absent to 7=extreme. Higher score indicating greater severity of symptoms", "populationDescription": "FAS", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "units on a scale", "timeFrame": "Baseline and Week 6", "groups": [{"id": "OG000", "title": "Placebo", "description": "Placebo: Once daily as tablets and capsules, orally"}, {"id": "OG001", "title": "Brexpiprazole", "description": "Brexpiprazole: 2-4 mg/day, once daily, tablets, orally"}, {"id": "OG002", "title": "Quetiapine Extended Release", "description": "Active Reference\n\nQuetiapine extended release: 400-800 mg/day, once daily, encapsulated tablets, orally"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "159"}, {"groupId": "OG001", "value": "150"}, {"groupId": "OG002", "value": "150"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-3.2", "spread": "0.4"}, {"groupId": "OG001", "value": "-4.0", "spread": "0.4"}, {"groupId": "OG002", "value": "-4.8", "spread": "0.3"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline to Week 6 in PANSS Marder Factor Scores: Uncontrolled Hostility/Excitement", "description": "The Positive and Negative Syndrome Scale (PANSS) is a clinician rated scale designed to measure severity of psychopathology in adult patients with schizophrenia, schizoaffective disorders and other psychotic disorders. It emphasizes positive and negative symptoms. The PANSS Marder Factor scores: uncontrolled hostility/excitement is calculated from 4 items (for example: excitement, hostility, and uncooperativeness).Symptom severity was rated on a 7-point scale, from 1=absent to 7=extreme. Higher score indicating greater severity of symptoms", "populationDescription": "FAS", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "units on a scale", "timeFrame": "Baseline and Week 6", "groups": [{"id": "OG000", "title": "Placebo", "description": "Placebo: Once daily as tablets and capsules, orally"}, {"id": "OG001", "title": "Brexpiprazole", "description": "Brexpiprazole: 2-4 mg/day, once daily, tablets, orally"}, {"id": "OG002", "title": "Quetiapine Extended Release", "description": "Active Reference\n\nQuetiapine extended release: 400-800 mg/day, once daily, encapsulated tablets, orally"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "159"}, {"groupId": "OG001", "value": "150"}, {"groupId": "OG002", "value": "150"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-1.8", "spread": "0.3"}, {"groupId": "OG001", "value": "-2.5", "spread": "0.3"}, {"groupId": "OG002", "value": "-2.8", "spread": "0.3"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline to Week 6 in PANSS Marder Factor Scores: Anxiety/Depression", "description": "The Positive and Negative Syndrome Scale (PANSS) is a clinician rated scale designed to measure severity of psychopathology in adult patients with schizophrenia, schizoaffective disorders and other psychotic disorders. It emphasizes positive and negative symptoms. The PANSS Marder Factor scores: anxiety/depression is calculated from 4 items (for example: anxiety, guilt feelings, and tension). Symptom severity was rated on a 7-point scale, from 1=absent to 7=extreme. Higher score indicating greater severity of symptoms", "populationDescription": "FAS", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "units on a scale", "timeFrame": "Baseline and Week 6", "groups": [{"id": "OG000", "title": "Placebo", "description": "Placebo: Once daily as tablets and capsules, orally"}, {"id": "OG001", "title": "Brexpiprazole", "description": "Brexpiprazole: 2-4 mg/day, once daily, tablets, orally"}, {"id": "OG002", "title": "Quetiapine Extended Release", "description": "Active Reference\n\nQuetiapine extended release: 400-800 mg/day, once daily, encapsulated tablets, orally"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "159"}, {"groupId": "OG001", "value": "150"}, {"groupId": "OG002", "value": "150"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-2.9", "spread": "0.2"}, {"groupId": "OG001", "value": "-3.2", "spread": "0.2"}, {"groupId": "OG002", "value": "-3.6", "spread": "0.2"}]}]}]}, {"type": "SECONDARY", "title": "Discontinuation Due to Lack of Efficacy During the Study", "description": "Discontinuation due to lack of efficacy was based on the primary reason for withdrawal", "populationDescription": "APTS", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of patients", "timeFrame": "Baseline to Week 6", "groups": [{"id": "OG000", "title": "Placebo", "description": "Placebo: Once daily as tablets and capsules, orally"}, {"id": "OG001", "title": "Brexpiprazole", "description": "Brexpiprazole: 2-4 mg/day, once daily, tablets, orally"}, {"id": "OG002", "title": "Quetiapine Extended Release", "description": "Active Reference\n\nQuetiapine extended release: 400-800 mg/day, once daily, encapsulated tablets, orally"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "161"}, {"groupId": "OG001", "value": "150"}, {"groupId": "OG002", "value": "153"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "14.91"}, {"groupId": "OG001", "value": "6.67"}, {"groupId": "OG002", "value": "7.19"}]}]}]}, {"type": "SECONDARY", "title": "Response Rate at Week 6", "description": "The response rate was defined as a reduction of \u226530% from baseline in PANSS total score OR a CGI-I score of 1 or 2", "populationDescription": "FAS (last assessment)", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of responders", "timeFrame": "Baseline and Week 6", "groups": [{"id": "OG000", "title": "Placebo", "description": "Placebo: Once daily as tablets and capsules, orally"}, {"id": "OG001", "title": "Brexpiprazole", "description": "Brexpiprazole: 2-4 mg/day, once daily, tablets, orally"}, {"id": "OG002", "title": "Quetiapine Extended Release", "description": "Active Reference\n\nQuetiapine extended release: 400-800 mg/day, once daily, encapsulated tablets, orally"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "159"}, {"groupId": "OG001", "value": "150"}, {"groupId": "OG002", "value": "150"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "32.1"}, {"groupId": "OG001", "value": "48.7"}, {"groupId": "OG002", "value": "62.7"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline to Week 6 in PSP Total Score", "description": "The Personal and Social Performance Scale (PSP) is a clinician-rated scale designed and validated to measure a patient's current level of social functioning. The PSP scale consists of a 100-point single-item rating scale, subdivided into 10 equal intervals. Scores of 1 to 10 indicate lack of autonomy in basic functioning, whereas scores of 91 to 100 reflect excellent functioning. The total score is rated by the investigator and is based on an algorithm which takes both the ratings of the 4 primary domains of PSP, and the combination of these ratings into account. The 4 primary domains are: socially useful activities (including work and study), personal and social relationships, self-care, and disturbing and aggressive behaviours. The 4 domains are assessed on a 6-point scale, from absent to very severe. A higher score indicates a better performance.", "populationDescription": "FAS. PSP was collected at Baseline, Day 21 and Day 42 only, due to the windowing only patients with PSP assessments between Days 15 to 27 and after Day 35 were included in this analysis; the number of participants analysed is therefore smaller than the defined FAS and also smaller than other PSP analyses using LOCF.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "units on a scale", "timeFrame": "Baseline and Week 6", "groups": [{"id": "OG000", "title": "Placebo", "description": "Placebo: Once daily as tablets and capsules, orally"}, {"id": "OG001", "title": "Brexpiprazole", "description": "Brexpiprazole: 2-4 mg/day, once daily, tablets, orally"}, {"id": "OG002", "title": "Quetiapine Extended Release", "description": "Active Reference\n\nQuetiapine extended release: 400-800 mg/day, once daily, encapsulated tablets, orally"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "139"}, {"groupId": "OG001", "value": "133"}, {"groupId": "OG002", "value": "138"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "9.4", "spread": "1.0"}, {"groupId": "OG001", "value": "13.0", "spread": "1.0"}, {"groupId": "OG002", "value": "15.3", "spread": "1.0"}]}]}]}, {"type": "SECONDARY", "title": "PSP Functional Remission Rate at Week 6", "description": "The PSP functional remission rate was defined as a PSP total score \u226571", "populationDescription": "FAS (last assessment). Patients who have no post-baseline PSP values available were not included as response is defined based on change from baseline and no baseline carried forward analysis was planned; the number of participants analysed is therefore smaller than the defined FAS.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of remitters", "timeFrame": "Week 6", "groups": [{"id": "OG000", "title": "Placebo", "description": "Placebo: Once daily as tablets and capsules, orally"}, {"id": "OG001", "title": "Brexpiprazole", "description": "Brexpiprazole: 2-4 mg/day, once daily, tablets, orally"}, {"id": "OG002", "title": "Quetiapine Extended Release", "description": "Active Reference\n\nQuetiapine extended release: 400-800 mg/day, once daily, encapsulated tablets, orally"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "157"}, {"groupId": "OG001", "value": "146"}, {"groupId": "OG002", "value": "146"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "5.7"}, {"groupId": "OG001", "value": "9.6"}, {"groupId": "OG002", "value": "14.4"}]}]}]}, {"type": "SECONDARY", "title": "PSP Functional Response Rate at Week 6", "description": "The PSP functional response rate was defined as \u226510 point improvement from Baseline on the PSP total score", "populationDescription": "FAS (last assessment). Patients who have no post-baseline PSP values available were not included as response is defined based on change from baseline and no baseline carried forward analysis was planned; the number of participants analysed is therefore smaller than the defined FAS.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of responders", "timeFrame": "Week 6", "groups": [{"id": "OG000", "title": "Placebo", "description": "Placebo: Once daily as tablets and capsules, orally"}, {"id": "OG001", "title": "Brexpiprazole", "description": "Brexpiprazole: 2-4 mg/day, once daily, tablets, orally"}, {"id": "OG002", "title": "Quetiapine Extended Release", "description": "Active Reference\n\nQuetiapine extended release: 400-800 mg/day, once daily, encapsulated tablets, orally"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "157"}, {"groupId": "OG001", "value": "146"}, {"groupId": "OG002", "value": "146"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "36.3"}, {"groupId": "OG001", "value": "53.4"}, {"groupId": "OG002", "value": "64.4"}]}]}]}, {"type": "SECONDARY", "title": "PSP Domain D: Disturbing and Aggressive Behaviours at Week 6", "description": "PSP domain D: disturbing and aggressive behaviours were categorised as \"aggressive\" (corresponding to mild, manifest, marked, severe, or very severe) or \"nonaggressive\" (corresponding to absent)", "populationDescription": "FAS. As this was based on observed cases, only patients who have PSP assessment at Week 6 were included in this analysis; the number of participants analysed is therefore smaller than the defined FAS and also smaller than other PSP analyses where last assessment carried forward was used.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of aggressive patients", "timeFrame": "Week 6", "groups": [{"id": "OG000", "title": "Placebo", "description": "Placebo: Once daily as tablets and capsules, orally"}, {"id": "OG001", "title": "Brexpiprazole", "description": "Brexpiprazole: 2-4 mg/day, once daily, tablets, orally"}, {"id": "OG002", "title": "Quetiapine Extended Release", "description": "Active Reference\n\nQuetiapine extended release: 400-800 mg/day, once daily, encapsulated tablets, orally"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "112"}, {"groupId": "OG001", "value": "114"}, {"groupId": "OG002", "value": "126"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "30.4"}, {"groupId": "OG001", "value": "27.2"}, {"groupId": "OG002", "value": "22.2"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "Baseline to end of treatment (Week 6)", "description": "Treatment-Emergent Adverse Events are reported in this section", "eventGroups": [{"id": "EG000", "title": "Placebo", "description": "Placebo: Once daily as tablets and capsules, orally", "seriousNumAffected": 6, "seriousNumAtRisk": 161, "otherNumAffected": 44, "otherNumAtRisk": 161}, {"id": "EG001", "title": "Brexpiprazole", "description": "Brexpiprazole: 2-4 mg/day, once daily, tablets, orally", "seriousNumAffected": 7, "seriousNumAtRisk": 150, "otherNumAffected": 48, "otherNumAtRisk": 150}, {"id": "EG002", "title": "Quetiapine", "description": "Active Reference\n\nQuetiapine extended release: 400-800 mg/day, once daily, encapsulated tablets, orally", "seriousNumAffected": 2, "seriousNumAtRisk": 153, "otherNumAffected": 73, "otherNumAtRisk": 153}], "seriousEvents": [{"term": "Type 2 diabetes mellitus", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 161}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 150}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 153}]}, {"term": "Grand mal convulsion", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 161}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 150}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 153}]}, {"term": "Anxiety", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 161}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 150}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 153}]}, {"term": "Psychotic disorder", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 161}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 150}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 153}]}, {"term": "Schizophrenia", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 161}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 150}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 153}]}, {"term": "Schizophrenia, paranoid type", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 161}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 150}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 153}]}, {"term": "Suicide attempt", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 161}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 150}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 153}]}, {"term": "Angioedema", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 161}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 150}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 153}]}], "otherEvents": [{"term": "Dry mouth", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 161}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 150}, {"groupId": "EG002", "numAffected": 13, "numAtRisk": 153}]}, {"term": "Weight increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 6, "numAtRisk": 161}, {"groupId": "EG001", "numAffected": 8, "numAtRisk": 150}, {"groupId": "EG002", "numAffected": 20, "numAtRisk": 153}]}, {"term": "Akathisia", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 161}, {"groupId": "EG001", "numAffected": 9, "numAtRisk": 150}, {"groupId": "EG002", "numAffected": 6, "numAtRisk": 153}]}, {"term": "Dizziness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 161}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 150}, {"groupId": "EG002", "numAffected": 18, "numAtRisk": 153}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 11, "numAtRisk": 161}, {"groupId": "EG001", "numAffected": 8, "numAtRisk": 150}, {"groupId": "EG002", "numAffected": 9, "numAtRisk": 153}]}, {"term": "Sedation", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 161}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 150}, {"groupId": "EG002", "numAffected": 8, "numAtRisk": 153}]}, {"term": "Somnolence", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 8, "numAtRisk": 161}, {"groupId": "EG001", "numAffected": 7, "numAtRisk": 150}, {"groupId": "EG002", "numAffected": 34, "numAtRisk": 153}]}, {"term": "Insomnia", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 10, "numAtRisk": 161}, {"groupId": "EG001", "numAffected": 13, "numAtRisk": 150}, {"groupId": "EG002", "numAffected": 4, "numAtRisk": 153}]}, {"term": "Schizophrenia", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 11, "numAtRisk": 161}, {"groupId": "EG001", "numAffected": 6, "numAtRisk": 150}, {"groupId": "EG002", "numAffected": 4, "numAtRisk": 153}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictiveAgreement": false}, "pointOfContact": {"title": "Email contact via", "organization": "H. Lundbeck A/S", "email": "LundbeckClinicalTrials@Lundbeck.com"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-26"}, "conditionBrowseModule": {"meshes": [{"id": "D000012559", "term": "Schizophrenia"}], "ancestors": [{"id": "D000019967", "term": "Schizophrenia Spectrum and Other Psychotic Disorders"}, {"id": "D000001523", "term": "Mental Disorders"}], "browseLeaves": [{"id": "M15376", "name": "Schizophrenia", "asFound": "Schizophrenia", "relevance": "HIGH"}, {"id": "M4815", "name": "Mental Disorders", "relevance": "LOW"}, {"id": "M14473", "name": "Psychotic Disorders", "relevance": "LOW"}, {"id": "M21838", "name": "Schizophrenia Spectrum and Other Psychotic Disorders", "relevance": "LOW"}, {"id": "T170", "name": "Acute Graft Versus Host Disease", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BXM", "name": "Behaviors and Mental Disorders"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "Rare", "name": "Rare Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000069348", "term": "Quetiapine Fumarate"}, {"id": "C000591922", "term": "Brexpiprazole"}], "ancestors": [{"id": "D000000928", "term": "Antidepressive Agents"}, {"id": "D000011619", "term": "Psychotropic Drugs"}, {"id": "D000014150", "term": "Antipsychotic Agents"}, {"id": "D000014149", "term": "Tranquilizing Agents"}, {"id": "D000002492", "term": "Central Nervous System Depressants"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000018490", "term": "Serotonin Agents"}, {"id": "D000018377", "term": "Neurotransmitter Agents"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000018491", "term": "Dopamine Agonists"}, {"id": "D000015259", "term": "Dopamine Agents"}], "browseLeaves": [{"id": "M399", "name": "Quetiapine Fumarate", "asFound": "Sexual", "relevance": "HIGH"}, {"id": "M293045", "name": "Brexpiprazole", "asFound": "Pars", "relevance": "HIGH"}, {"id": "M4247", "name": "Antidepressive Agents", "relevance": "LOW"}, {"id": "M14474", "name": "Psychotropic Drugs", "relevance": "LOW"}, {"id": "M16904", "name": "Antipsychotic Agents", "relevance": "LOW"}, {"id": "M15512", "name": "Serotonin", "relevance": "LOW"}, {"id": "M20504", "name": "Neurotransmitter Agents", "relevance": "LOW"}, {"id": "M7473", "name": "Dopamine", "relevance": "LOW"}, {"id": "M20595", "name": "Dopamine Agonists", "relevance": "LOW"}, {"id": "M17962", "name": "Dopamine Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "CNSDep", "name": "Central Nervous System Depressants"}, {"abbrev": "PsychDr", "name": "Psychotropic Drugs"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "CaAg", "name": "Cardiotonic Agents"}]}}, "hasResults": true}